Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week, single-arm, open-label extension study

RATIONALE: Cariprazine, a dopamine D(3)/D(2) receptor partial agonist antipsychotic, demonstrated efficacy and tolerability in 6-week, randomized, placebo-controlled schizophrenia trials. Schizophrenia is a chronic disorder that requires continuous treatment; therefore, the long-term safety and tole...

Descripción completa

Detalles Bibliográficos
Autores principales: Durgam, Suresh, Greenberg, William M., Li, Dayong, Lu, Kaifeng, Laszlovszky, Istvan, Nemeth, Gyorgy, Migliore, Raffaele, Volk, Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5203812/
https://www.ncbi.nlm.nih.gov/pubmed/27807604
http://dx.doi.org/10.1007/s00213-016-4450-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5203812/
https://www.ncbi.nlm.nih.gov/pubmed/27807604
http://dx.doi.org/10.1007/s00213-016-4450-3

Ejemplares similares